UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
Arena Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $.0001 par value
(Title of Class of Securities)
040047102
(CUSIP Number)
March 11, 2002
(Date of Event which Requires filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 040047102
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
HBM BioVentures AG
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 1,604,665
----------------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY -0-
----------------------------------------------------------
OWNED BY EACH 7 SOLE DISPOSITIVE POWER
REPORTING 1,604,665
----------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH -0-
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,604,665
--------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
Not Applicable.
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.82%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
2
ITEM 1. (a) Name of Issuer:
Arena Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
6166 Nancy Ridge Drive, San Diego, CA 92121
ITEM 2. (a) Name of Person Filing:
HBM BioVentures AG
(b) Address of Principal Business Office or, if none, Residence:
The following is the address of the principal business office of
the filing person:
Zugerstrasse 50
6340 Baar
Switzerland
(c) Citizenship:
Switzerland
(d) Title of Class of Securities:
Common Stock, $.0001 par value
(e) CUSIP Number:
040047102
ITEM 3. If this Statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or
(c), check whether the person filing is a:
Not applicable.
ITEM 4. Ownership
(a) Amount Beneficially Owned: 1,604,665
(b) Percent of Class: 5.82%
(c) Number of shares as to which the person has:.
(i) Sole power to vote or to direct the vote 1,604,665
(ii) Shared power to vote or to direct the vote -0-
(iii) Sole power to dispose or to direct the disposition
1,604,665
(iv) Shared power to dispose or to direct the disposition -0-
3
ITEM 5. Ownership of Five Percent or Less of a Class
Not applicable.
ITEM 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
ITEM 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company
1,034,665 of the shares beneficially owned by the Reporting Person and
reported herein are owned directly by International BM Biomedicine
Holdings Inc. and indirectly by the Reporting Person pursuant to Rule
13d-3(d)(1)(i).
ITEM 8. Identification and Classification of Members of the Group
Not applicable.
ITEM 9. Notice of Dissolution of Group
Not applicable.
ITEM 10. Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction
having that purpose or effect.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: March 21, 2002
/s/ Joachim Rudolf
-------------------------------
By: Joachim Rudolf
Title: Chief Financial Officer
4